Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Trevi Therapeutics, Inc. (TRVI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/14/2023 4 Delfini Lisa (CFO) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Sold 682 shares @ $2.36, valued at $1.6k
Exercised 2,292 options to buy @ $0.511, valued at $1.2k
08/11/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis published in NEJM Evidence Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., August 10, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis , other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ended June 30, 2023, as well as provided business updates. ..."
07/12/2023 4 Delfini Lisa (CFO) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Sold 687 shares @ $2.34, valued at $1.6k
Exercised 2,292 options to buy @ $0.511, valued at $1.2k
06/30/2023 4 Mathers Edward T (Director) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $2.27, valued at $68.1k
06/30/2023 4 Cassella James V (Director) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $2.27, valued at $68.1k
06/30/2023 4 Heffernan Michael Thomas (Director) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $2.27, valued at $68.1k
06/30/2023 4 Meeker David P (Director) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $2.27, valued at $68.1k
06/30/2023 4 Colangelo Dominick (Director) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $2.27, valued at $68.1k
06/30/2023 4 VANLENT ANNE (Director) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Granted 30,000 options to buy @ $2.27, valued at $68.1k
06/29/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/29/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "TREVI THERAPEUTICS, INC. By: /s/ Jennifer Good Name: Jennifer Good Title: Chief Executive Officer [Signature Page to Certificate of Amendment]"
06/12/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update Initiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral nalbuphine ER for the treatment of chronic cough in idiopathic pulmonary fibrosis Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., May 11, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis , other chronic cough indications and prurigo nodularis , today announced financial results for the quarter ended March 31, 2023, as well as provided business updates. ..."
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/14/2023 8-K Quarterly results
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. EDT New Haven, Conn., March 16, 2023 – Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis and other chronic cough indications, and for the treatment of prurigo nodularis, today announced financial results for the quarter and year ended December 31, 2022, as well as provided business updates. "Following the very encouraging results from our Phase 2 CANAL trial in IPF chronic co..."
03/15/2023 4 Delfini Lisa (CFO) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Sold 892 shares @ $1.7532, valued at $1.6k
Exercised 2,291 options to buy @ $0.511, valued at $1.2k
03/08/2023 4 Simon Farrell (Chief Commercial Officer) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Exercised 18,750 options to buy @ $0.511, valued at $9.6k
02/14/2023 SC 13G/A Venrock Healthcare Capital Partners II, L.P. reports a 10% stake in Trevi Therapeutics, Inc.
02/14/2023 SC 13G/A Fairmount Funds Management LLC reports a 9.9% stake in TREVI THERAPEUTICS, INC.
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 5% stake in TREVI THERAPEUTICS, INC.
02/14/2023 SC 13G/A VIKING GLOBAL INVESTORS LP reports a 10% stake in Trevi Therapeutics, Inc.
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy